SCHEMBL4740853

SCHEMBL4740853

COc1ccc2c(c1)c(Nc1cccc(Cl)c1)nn2-c1cccc(C(C)O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 2/20 0.50
KDR P35968 1/20 0.42
LMNA P02545 3/20 0.41
MEN1 O00255 2/20 0.41
HPGD P15428 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GFER P55789 1/20 0.41
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
EGFR P00533 4/20 0.40
ERBB3 P21860 1/20 0.40
CDK1 P06493 2/20 0.39
CASR P41180 1/20 0.39
MAPT P10636 3/20 0.39
ABL1 P00519 2/20 0.39
PLK1 P53350 2/20 0.38
MAP4K4 O95819 1/20 0.38
AURKB Q96GD4 1/20 0.38
SRPK1 Q96SB4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4741937 0.84 FADS1 (0.45) FADS1KDRLMNAMEN1HPGD
SCHEMBL4741047 0.83 FADS1 (0.46) FADS1KDRLMNAMEN1HPGD
SCHEMBL4742030 0.83 MAPT (0.52) FADS1KDRLMNAMEN1HPGD
SCHEMBL4741035 0.83 MEN1 (0.50) FADS1KDRLMNAMEN1HPGD
SCHEMBL4740964 0.83 FADS1 (0.48) FADS1KDRLMNAMEN1HPGD
SCHEMBL4738667 0.82 MAPT (0.48) FADS1KDRLMNAMEN1KMT2A
SCHEMBL4737856 0.82 FADS1 (0.48) FADS1KDRLMNAMEN1HPGD
SCHEMBL4742063 0.82 FADS1 (0.50) FADS1KDRLMNAMEN1HPGD
SCHEMBL4738591 0.81 FADS1 (0.46) FADS1KDRLMNAMEN1HPGD
SCHEMBL4737805 0.81 FADS1 (0.48) FADS1KDRLMNAMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders LEXICON PHARMACEUTICALS, INC. 2008-08-21 US disclosed
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer LEXICON PHARMACEUTICALS, INC. 2008-08-14 US disclosed
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer TNF, IL6, CXCL8 FADS1 1059/4885KDR 1066/4885LMNA 1776/4885
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders CPT1B, CPT1A, SHBG FADS1 270/4885KDR 4840/4885LMNA 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.